Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury

Kidney and Blood Pressure Research

Volumn 29, Issue 3, 2006, Pages 165-174

  Aravindan, Natarajan ^a,d   Samuels, Joshua ^b   Riedel, Bernhard ^a   Shaw, Andrew ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Circulation, renal; Fenoldopam; Gene expression; Ischemia reperfusion; Oxygen delivery, renal

Indexed keywords

FENOLDOPAM; RNA; SODIUM CHLORIDE;

ADOLESCENT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEMODYNAMICS; KIDNEY CORTEX; KIDNEY ISCHEMIA; KIDNEY MEDULLA; KIDNEY PERFUSION; MALE; NONHUMAN; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; RAT; REPERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TISSUE OXYGENATION;

ACUTE DISEASE; ANALYSIS OF VARIANCE; ANGIOGENESIS INDUCING AGENTS; ANIMALS; FENOLDOPAM; GENE EXPRESSION REGULATION; ISCHEMIA; KIDNEY; KIDNEY DISEASES; MALE; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; REPERFUSION INJURY;

EID: 33750185154     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095350     Document Type: Article

References (35)

1. Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 1996;334:1448-1460.
2. Safi HJ, Harlin SA, Miller CC, Iliopoulos DC, Joshi A, Mohasci TG, Zippel R, Letsou GV: Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. J Vase Surg 1996;24:338-344.
3. Brady HR BB, Clarkson MR, Lieberthal W: Acute renal failure; in Brenner BM (ed): The Kidney, ed 6. Philadelphia, Saunders, 2000, pp 1201-1262.
4. Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D, Epstein M, Luther RR: The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999;27:1832-1837.
5. Dishart MK, Kellum JA: An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs 2000;59:79-91.
6. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM: Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997;29:115-122.
7. Shusterman NH, Elliott WJ, White WB: Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993;95:161-168.
8. Horn PT, Murphy MB: Therapeutic applications of drugs acting on peripheral dopamine receptors. J Clin Pharmacol 1990;30:674-679.
9. Bodmann KF, Troster S, Clemens R, Schuster HP: Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin Investig 1993;72:60-64.
10. Murphy MB, McCoy CE, Weber RR, Frederickson ED, Douglas FL, Goldberg LI: Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopaminel agonist fenoldopam. Circulation 1987;76:1312-1318.
11. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A: Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 2002;90:784-791.
12. Yamaguchi I, Yao L, Sanada H, Ozono R, Mouradian MM, Jose PA, Carey RM, Felder RA: Dopamine D1A receptors and renin release in rat juxtaglomerular cells. Hypertension 1997;29:962-968.
13. Andrade-Mena CE: Inhibition of lipopolysaccharide-induced alpha/beta-interferon synthesis by dopamine and the dopamine-1 agonist fenoldopam. J Neuroimmunol 1989;22:47-53.
14. National Research Council: Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Washington, National Academy Press1996, pp 1-118.
15. Liss P, Nygren A, Erikson U, Ulfendahl HR: Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 1998;53:698-702.
16. Samuels J, Finkel K, Gubert M, Johnson T, Shaw A: Effect of fenoldopam mesylate in critically ill patients at risk for acute renal failure is dose dependent. Ren Fail 2005;27:101-105.
17. Aravindan N, Mohan N, Andrew DS: Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of ischemic acute renal failure. J Cardiothorac Vasc Anesth 2006;20:179-186.
18. Yamamoto T, Tada T, Brodsky SV, Tanaka H, Noiri E, Kajiya F, Goligorsky MS: Intravital videomicroscopy of peritubular capillaries in renal ischemia. Am J Physiol Renal Physiol 2002;282:F1150-F1155.
19. Brezis M, Rosen S, Silva P, Epstein FH: Renal ischemia: a new perspective. Kidney Int 1984;26:375-383.
20. Kien ND, Moore PG, Jaffe RS: Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth Analg 1992;74:72-78.
21. Miller Q, Peyton BD, Cohn EJ, Holmes GF, Harlin SA, Bird ET, Harre JG, Miller ML, Riley KD, Hogan MB, Taylor A: The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping. Ann Vasc Surg 2003;17:656-662.
22. Umrani DN, Goyal RK: Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats. Clin Exp Hypertens 2003;25:221-233.
23. Hunter DW, Chamsuddin A, Bjarnason H, Kowalik K: Preventing contrast-induced nephropathy with fenoldopam. Tech Vasc Interv Radiol 2001;4:53-56.
24. Umrani DN, Goyal RK: Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats. Clin Exp Hypertens 2002;24:207-219.
25. Chu VL, Cheng JW: Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann Pharmacother 2001;35:1278-1282.
26. Halpenny M, Markos F, Snow HM, Duggan PF, Gaffney E, O'Connell DP, Shorten GD: Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs. Crit Care Med 2001;29:855-860.
27. Halpenny M, Markos F, Snow HM, Duggan PF, Gaffney E, O'Connell DP, Shorten GD: The effects of fenoldopam on renal blood flow and tubular function during aortic cross-clamping in anaesthetized dogs. Eur J Anaesthesiol 2000;17:491-498.
28. Singer I, Epstein M: Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998;31:743-755.
29. Holder N, Klein R: Eph receptors and ephrins: effectors of morphogenesis. Development 1999;126:2033-2044.
30. Gobe G, Zhang XJ, Willgoss DA, Schoch E, Hogg NA, Endre ZH: Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol 2000;11:454-467.
31. Humes HD, Cieslinski DA, Coimbra TM, Messana JM, Galvao C: Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 1989;84:1757-1761.
32. Mitola S, Strasly M, Prato M, Ghia P, Bussolino F: IL-12 regulates an endothelial celllymphocyte network: effect on metalloproteinase-9 production. J Immunol 2003;171:3725-3733.
33. Koken T, Serteser M, Kahraman A, Akbulut G, Dilek ON: Which is more effective in the prevention of renal ischemia-reperfusioninduced oxidative injury in the early period in mice: interleukin (IL)-10 or anti-IL-12? Clin Biochem 2004;37:50-55.
34. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy-Ullrich JE, Hugo C: Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 2004;65:459-468.
35. Brienza N, Malcangi V, Dalfino L, Trerotoli P, Guagliardi C, Bortone D, Faconda G, Ribezzi M, Ancona G, Bruno F, Fiore T: A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006;34:707-714.